Ascendis Pharma A/S (ASND) Rating Lowered to Hold at BidaskClub

Ascendis Pharma A/S (NASDAQ:ASND) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a report issued on Saturday.

Other research analysts have also issued research reports about the company. Bank of America lifted their price target on Ascendis Pharma A/S from $36.00 to $46.00 in a research report on Thursday, September 28th. JPMorgan Chase & Co. set a $50.00 price target on Ascendis Pharma A/S and gave the stock a “buy” rating in a research report on Wednesday, January 3rd. HC Wainwright reaffirmed a “buy” rating on shares of Ascendis Pharma A/S in a research report on Wednesday, December 13th. Wells Fargo & Co reaffirmed a “buy” rating and set a $51.00 price target on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. Finally, Credit Suisse Group reaffirmed an “outperform” rating and set a $50.00 price target (up previously from $30.00) on shares of Ascendis Pharma A/S in a research report on Friday, September 22nd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company’s stock. Ascendis Pharma A/S presently has a consensus rating of “Buy” and an average target price of $38.79.

Ascendis Pharma A/S (ASND) opened at $39.92 on Friday. The company has a market capitalization of $1,450.00 and a P/E ratio of -10.08. Ascendis Pharma A/S has a 12-month low of $19.88 and a 12-month high of $42.00.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. acquired a new position in Ascendis Pharma A/S during the third quarter worth approximately $7,163,000. RA Capital Management LLC increased its holdings in shares of Ascendis Pharma A/S by 3.2% in the second quarter. RA Capital Management LLC now owns 5,580,690 shares of the biotechnology company’s stock valued at $154,920,000 after purchasing an additional 170,700 shares during the period. VHCP Management II LLC increased its holdings in shares of Ascendis Pharma A/S by 21.6% in the second quarter. VHCP Management II LLC now owns 986,492 shares of the biotechnology company’s stock valued at $27,385,000 after purchasing an additional 175,000 shares during the period. California Public Employees Retirement System acquired a new position in shares of Ascendis Pharma A/S in the second quarter valued at approximately $430,000. Finally, Janus Henderson Group PLC acquired a new position in shares of Ascendis Pharma A/S in the second quarter valued at approximately $15,403,000. 78.93% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Ascendis Pharma A/S (ASND) Rating Lowered to Hold at BidaskClub” was originally published by Equities Focus and is owned by of Equities Focus. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.equitiesfocus.com/2018/01/08/ascendis-pharma-a-s-asnd-rating-lowered-to-hold-at-bidaskclub.html.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply